CRL Charles River Laboratories

company

SEC Filings & Insider Trading Activity 2026

Management Discussion & Analysis

• • Revenue DSA declined in fiscal 2025 due to lower study volumes; RMS revenue increased driven by large research models and pricing; Manufacturing Microbial Solutions grew robustly
• • Goodwill impairment of $165M in Biologics Solutions for 2025 due to reduced performance; impairment $215M in 2024 in same unit
• • Best segment: Manufacturing Microbial Solutions with robust growth, share gains, and higher sales; Worst segment: DSA with declined revenue and backlog falling to $1.9B from $2.0B
• • Capital allocation: Acquired KF for $510M, Noveprim controlling interest for $392.4M, SAMDI for $62.8M, PathoQuest option for ~$60M; acquisitions funded by cash and Credit Facility
• • Forward outlook: $300M cost savings by 2026; focus on strategic acquisitions, partnerships, and divestments of 7% 2025 revenue; cautious early-stage R&D spending remains a risk

Business Overview

• • Core business model: Preclinical and clinical laboratory services for drug discovery and development
• • No new products, services, or business segments introduced or emphasized in this fiscal year
• • Maintained existing strategic practices, including strict compliance on timing of equity awards and insider trading policies
• • Fiscal 2025 equity awards policy with no stock options granted near earnings releases to avoid insider trading risks
• • No errors or clawbacks of executive compensation reported during or after fiscal 2025

Risk Factors

• • Cybersecurity risk governance by Board Audit Committee with quarterly reviews and direct CIO, CISO reporting to Audit Chair
• • Heavy reliance on Chief Information Officer with 30+ years experience for global IT risk oversight and digital strategy execution
• • Cybersecurity assessments include third-party audits, vulnerability tests, and industry standard compliance frameworks
• • Incident Response Plan mandates escalation to Audit Committee for significant cybersecurity events
• • No specific regulatory, geopolitical, operational supply chain, competitive, or financial risks detailed in this section

What are the latest CRL SEC filings in 2026?

Charles River Laboratories (CRL) has filed a 10-K annual report on February 18, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on August 5, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did CRL file its most recent 10-K annual report?

Charles River Laboratories (CRL) filed its most recent 10-K annual report on February 18, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view CRL 10-Q quarterly reports?

Charles River Laboratories (CRL)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every CRL 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has CRL filed recently?

Charles River Laboratories (CRL)'s most recent 8-K was filed on August 5, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find CRL insider trading activity (Form 4)?

SignalX aggregates every CRL Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does CRL file with the SEC?

Charles River Laboratories (CRL) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new CRL filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Charles River Laboratories (CRL).

What is CRL's SEC CIK number?

Charles River Laboratories (CRL)'s SEC CIK (Central Index Key) number is 1100682. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1100682 to look up all CRL filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find CRL return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Charles River Laboratories (CRL) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.